These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26362098)

  • 1. Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine.
    Sanders BP; Edo-Matas D; Papic N; Schuitemaker H; Custers JHHV
    Vaccine; 2015 Oct; 33(42):5498-5502. PubMed ID: 26362098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.
    Sanders BP; Edo-Matas D; Custers JH; Koldijk MH; Klaren V; Turk M; Luitjens A; Bakker WA; Uytdehaag F; Goudsmit J; Lewis JA; Schuitemaker H
    Vaccine; 2013 Jan; 31(5):850-6. PubMed ID: 23123018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV.
    Sanders BP; Oakes Ide L; van Hoek V; Liu Y; Marissen W; Minor PD; Wimmer E; Schuitemaker H; Custers JH; Macadam A; Cello J; Edo-Matas D
    Vaccine; 2015 Nov; 33(48):6611-6. PubMed ID: 26529068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus.
    Georgescu MM; Delpeyroux F; Crainic R
    J Gen Virol; 1995 Sep; 76 ( Pt 9)():2343-8. PubMed ID: 7561775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of antigenic profiles of inactivated poliovirus vaccine and vaccine-derived polioviruses by block-ELISA method.
    Rezapkin G; Martin J; Chumakov K
    Biologicals; 2005 Mar; 33(1):29-39. PubMed ID: 15713554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen chimaeras of poliovirus as potential new vaccines.
    Burke KL; Dunn G; Ferguson M; Minor PD; Almond JW
    Nature; 1988 Mar; 332(6159):81-2. PubMed ID: 2450279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
    Shimizu H
    Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic structure of poliovirus in inactivated vaccines.
    Ferguson M; Wood DJ; Minor PD
    J Gen Virol; 1993 Apr; 74 ( Pt 4)():685-90. PubMed ID: 7682250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Manipulation of the cellular binding properties of poliovirus: implications for non-target effects of recombinant vaccines.
    Whelan SP; Evans D; Almond JW
    Dev Biol Stand; 1995; 84():129-36. PubMed ID: 7796945
    [No Abstract]   [Full Text] [Related]  

  • 11. Inactivated vaccines based on alternatives to wild-type seed virus.
    Chumakov K; Dragunsky E; Ivshina A; Enterline J; Wells V; Nomura T; Gromeier M; Wimmer E
    Dev Biol (Basel); 2001; 105():171-7. PubMed ID: 11763325
    [No Abstract]   [Full Text] [Related]  

  • 12. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of inactivated poliovirus vaccine derived from Sabin strains.
    Simizu B; Abe S; Yamamoto H; Tano Y; Ota Y; Miyazawa M; Horie H; Satoh K; Wakabayashi K
    Biologicals; 2006 Jun; 34(2):151-4. PubMed ID: 16679028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains.
    Hamidi A; Bakker WA
    Pharm Pat Anal; 2012 Nov; 1(5):589-99. PubMed ID: 24236927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
    Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
    Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new RT-PCR assay for the identification of the predominant recombination types in 2C and 3D genomic regions of vaccine-derived poliovirus strains.
    Pliaka V; Dedepsidis E; Kyriakopoulou Z; Mpirli K; Tsakogiannis D; Pratti A; Levidiotou-Stefanou S; Markoulatos P
    Mol Cell Probes; 2010 Jun; 24(3):115-23. PubMed ID: 19948215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
    Minor PD
    Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961.
    Cutrone R; Lednicky J; Dunn G; Rizzo P; Bocchetta M; Chumakov K; Minor P; Carbone M
    Cancer Res; 2005 Nov; 65(22):10273-9. PubMed ID: 16288015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High resolution identity testing of inactivated poliovirus vaccines.
    Mee ET; Minor PD; Martin J
    Vaccine; 2015 Jul; 33(30):3533-41. PubMed ID: 26049003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.